Geistlich Pharma North America, Inc. has New Vice President of Scientific and Clinical Affairs

PRINCETON, N.J., Nov. 8, 2017 /PRNewswire/ -- Geistlich Pharma North America, Inc. announces that Fotinos (Foti) S. Panagakos, DMD, PhD, is joining the Geistlich U.S. leadership team as Vice President of Scientific and Clinical Affairs. Dr. Panagakos will lead the U.S. clinical science team activities related to the development of clinical studies, publications, and continuing to strengthen relationships with regional and national professional associations aligned with regenerative dentistry.

Greg Bosch, CEO of Geistlich Pharma NA, stated: "We are pleased to welcome Foti to the Geistlich family. He joins a team focused on further developing Geistlich North America's biomaterial as the leader in hard and soft-tissue regeneration in dentistry."

Dr. Panagakos joins Geistlich with broad experience in the oral health field inclusive of his time in dental education from 1993 to 2005 at The University of Medicine and Dentistry of New Jersey (now Rutgers University School of Dentistry). Most recently, Dr. Panagakos completed twelve successful years with Colgate, with his last role as Global Director, Scientific Affairs and Research Relations. At Colgate, he partnered and collaborated with the leading oral health organizations around the world on various projects, from proof of concept studies, multicenter randomized control trials, and development and publication of numerous scholarly works. He currently serves on several boards including the American Association of Periodontology Foundation, American Dental Association Foundation, Oral Health America and Children's Dental Health Project, as well on the dean's advisory boards at the University of Michigan, West Virginia University, and Columbia University.

"I am excited to be joining Geistlich and providing my clinical, academic and corporate oral health experiences to support the Geistlich team and continuing my long-standing relationships throughout dentistry." – Dr. Panagakos noted.

Dr. Panagakos received his Ph.D. in Biochemistry and Molecular Biology as well as his Doctor of Dental Medicine degree from the University of Medicine and Dentistry of New Jersey. He also received a Master's of Business Administration from Lehigh University. Currently, Dr. Panagakos is a Clinical Associate Professor in the Department of Restorative Dentistry at the Rutgers School of Dental Medicine. Additionally, Dr. Panagakos honorably served our country in the Army National Guard and Reserve for 12 years.

About Geistlich Pharma North America, Inc. –
Geistlich Pharma North America, Inc. continues to lead dental regeneration with its expanding family of predictable and proven biomaterials, including bone substitutes Geistlich Bio-Oss® and Geistlich Bio-Oss Collagen®, a resorbable bilayer collagen membrane, Geistlich Bio-Gide®, a soft-tissue regeneration collagen matrix, Geistlich Mucograft®, and introducing, Geistlich Mucograft® Seal, a 3D collagen matrix designed for soft-tissue regeneration around an implant or prosthetic. With over 160 years of Swiss tradition, Geistlich Biomaterials has been a trusted partner for dental regenerative solutions based upon continuous innovation, scientific collaboration, and a commitment to successful outcomes.

SOURCE Geistlich Pharma North America, Inc.

Related Links

http://www.geistlich-na.com